Eli Lilly and Stock Forecast, Price & News

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

Is Eli Lilly and a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

How has Eli Lilly and's stock been impacted by COVID-19 (Coronavirus)?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LLY shares have increased by 75.0% and is now trading at $245.05.
View which stocks have been most impacted by COVID-19.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a decrease in short interest in December. As of December 31st, there was short interest totaling 4,790,000 shares, a decrease of 22.6% from the December 15th total of 6,190,000 shares. Based on an average daily trading volume, of 2,930,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the shares of the company are sold short.
View Eli Lilly and's Short Interest.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Eli Lilly and.

How can I listen to Eli Lilly and's earnings call?

Eli Lilly and will be holding an earnings conference call on Thursday, February 3rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings data on Monday, October, 25th. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $1.98 by $0.04. The business earned $6.77 billion during the quarter, compared to analyst estimates of $6.64 billion. Eli Lilly and had a net margin of 21.52% and a trailing twelve-month return on equity of 111.51%. The business's revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.54 EPS.
View Eli Lilly and's earnings history.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 13th. Investors of record on Tuesday, February 15th will be given a dividend of $0.98 per share on Thursday, March 10th. This represents a $3.92 annualized dividend and a yield of 1.60%. The ex-dividend date is Monday, February 14th. This is an increase from Eli Lilly and's previous quarterly dividend of $0.85.
View Eli Lilly and's dividend history.

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.38%. Eli Lilly and has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Eli Lilly and is 51.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.43% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and declared that its Board of Directors has approved a share buyback plan on Monday, May 3rd 2021, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY 2021 earnings guidance on Tuesday, November, 2nd. The company provided earnings per share guidance of $7.950-$8.050 for the period, compared to the Thomson Reuters consensus estimate of $6.800. The company issued revenue guidance of $27.20 billion-$27.60 billion, compared to the consensus revenue estimate of $23.52 billion.

What price target have analysts set for LLY?

16 Wall Street analysts have issued 1-year target prices for Eli Lilly and's stock. Their forecasts range from $236.00 to $325.00. On average, they expect Eli Lilly and's share price to reach $293.56 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:

• David A. Ricks, Chairman, President & Chief Executive Officer
• Anat Ashkenazi, Chief Financial Officer & Senior Vice President
• Timothy J. Garnett, Chief Medical Officer & VP-Global Medical
• Daniel M. Skovronsky, Chief Scientific Officer & Senior Vice President
• Diogo Rau, Senior VP, Chief Information & Digital Officer

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Who are some of Eli Lilly and's key competitors?

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Zogenix (ZGNX).
View all of LLY's competitors.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal London Asset Management Ltd. (0.09%), DNB Asset Management AS (0.05%), Bedel Financial Consulting Inc. (0.03%), Gateway Investment Advisers LLC (0.03%), State of Alaska Department of Revenue (0.02%) and Cohen Klingenstein LLC (0.02%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Donald A Zakrowski, Jackson P Tai, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

Which institutional investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Moody National Bank Trust Division, Crossmark Global Holdings Inc., Cohen Klingenstein LLC, State of Alaska Department of Revenue, Gateway Investment Advisers LLC, IBM Retirement Fund, and Clear Street Markets LLC. Company insiders that have sold Eli Lilly and company stock in the last year include Donald A Zakrowski, and Lilly Endowment Inc.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

Which institutional investors are buying Eli Lilly and stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Stock Yards Bank & Trust Co., Cacti Asset Management LLC, Cutler Group LP, Aries Wealth Management, Stonnington Group LLC, Alpha Cubed Investments LLC, Royal London Asset Management Ltd., and Sargent Bickham Lagudis LLC.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $245.05.

How much money does Eli Lilly and make?

Eli Lilly and has a market capitalization of $234.41 billion and generates $24.54 billion in revenue each year. The company earns $6.19 billion in net income (profit) each year or $6.56 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

Where are Eli Lilly and's headquarters?

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at (317) 276-2000, via email at [email protected], or via fax at 317-276-4878.